Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate (Macaca leonina). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). These preclinical results indicate that Nanocovax is safe and effective.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

Cell Mol Immunol. 2022 Jan 5:1-12. doi: 10.1038/s41423-021-00809-2. Online ahead of print.ABSTRACTAlthough antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candida...
Source: Cellular and Molecular Immunology - Category: Molecular Biology Authors: Source Type: research
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an ongoing pandemic. Detection and vaccination are essential for disease control, but they are distinct and complex operations that require significant improvements. Here, we developed an integrated detection and vaccination system to greatly simplify these efforts. We constructed recombinant baculoviruses to separately display the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2. Insect cells infected by the recombinant baculoviruses were used to generate a cell-based system to accurately detect patient ser...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study is unique because it is the first time researchers have targeted the receptor – the lock – with a bacterial extract and shown it protects against infection with live virus. We're essentially removing the lock from the cell wall so there's nothing for the virus'key to attach to, " said senior author Dr.  Donata Vercelli, professor of  cellular and molecular medicine at the UArizona College of Medicine – Tucson and professor of genetics at the BIO5 Institute.  When SARS-CoV-2 enters the lungs, it binds to receptors including the angiotensin converting enzym...
Source: The University of Arizona: Health - Category: Universities & Medical Training Authors: Source Type: research
The SARS-CoV-2 virus pandemic has put a massive struggle on health care systems. The only therapeutical option at the moment is vaccination. Viral mutation may reduce the efficacy of vaccines. We analyzed if a prophylactic immune cell activation using the bacterial extract Broncho Vaxom (BV) is beneficial during a coronavirus infection. To test our hypothesis we used a mouse coronavirus (MCoV) belonging to the same virus subfamily as SARS-CoV-2. BV was applied for 10 days before MCoV challenge. Viral load was significantly reduced in BV treated animals on day 4 and 10 compared to control (qPCR and histochemistry). BV treat...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway cell biology and immunopathology Source Type: research
Vaccine. 2021 Nov 8:S0264-410X(21)01435-3. doi: 10.1016/j.vaccine.2021.11.001. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall...
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
Vaccine. 2021 Nov 6:S0264-410X(21)01386-4. doi: 10.1016/j.vaccine.2021.10.053. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has already affected millions worldwide. The emergence of multiple SARS-CoV-2 variants may pose a significant threat to our efforts in controlling the pandemic. The impact of SARS-CoV-2 variants on the efficacy of available vaccines, therapeutics, and diagnostics is currently being investigated. SARS-CoV-2 has been implicated to be originated from animals due to cross-species jumping and raises zoonotic conce...
Source: Vaccine - Category: Allergy & Immunology Authors: Source Type: research
Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic since March 2020 and led to significant challenges to over 200 countries and regions all over the world. The establishment of highly pathogenic coronavirus animal model is beneficial for the study of vaccines and pathogenic mechanism of the virus. Laboratory mice, Syrian hamsters, Non-human primates and Ferrets have been used to establish animal models of emerging coronavirus infection. Different animal models can reproduce clinical infection symptoms at different levels. Appropriate animal model...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
This study provides novel epitope-based peptide vaccine candidates against SARS-CoV-2.
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Biomed Pharmacother. 2021 Oct 2;144:112276. doi: 10.1016/j.biopha.2021.112276. Online ahead of print.ABSTRACTThe potential emergence of SARS-CoV-2 variants capable of escaping vaccine-generated immune responses poses a looming threat to vaccination efforts and will likely prolong the duration of the COVID-19 pandemic. Additionally, the prevalence of beta coronaviruses circulating in animals and the precedent they have set in jumping into human populations indicates that they pose a continuous threat for future pandemics. Currently, only one therapeutic is approved by the U.S. Food and Drug Administration (FDA) for use in t...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
Nat Rev Mol Cell Biol. 2021 Oct 5:1-18. doi: 10.1038/s41580-021-00418-x. Online ahead of print.ABSTRACTThe unprecedented public health and economic impact of the COVID-19 pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been met with an equally unprecedented scientific response. Much of this response has focused, appropriately, on the mechanisms of SARS-CoV-2 entry into host cells, and in particular the binding of the spike (S) protein to its receptor, angiotensin-converting enzyme 2 (ACE2), and subsequent membrane fusion. This Review provides the structural and cellular fo...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Source Type: research
More News: Allergy & Immunology | Coronavirus | COVID-19 | Nanotechnology | Pandemics | Respiratory Medicine | SARS | Study | Syria Health | Vaccines | Veterinary Vaccinations